Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
These combined effects may explain why retatrutide has produced significant weight loss in clinical trials
Behaviour is what sustains it
Nonausea and GI side effects concentrate in the first 2 to 4 weeks and resolve for most patients by week 6 to 8
Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
20 Additionally, OW sema T2D had a positive impact on body weight, showing greater reductions in body weight than different comparators such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, daily subcutaneous GLP-1 RAs, other once-weekly subcutaneous GLP-1 RAs, and insulin medications tested in the trials
US$ 23.93
US$ 25.50
US$ 22.29
US$ 26.01
US$ 23.20
US$ 21.38
